Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. (Nasdaq: IMMX) generates a steady flow of news as a clinical-stage biopharmaceutical company advancing cell therapies for relapsed/refractory AL amyloidosis and other serious diseases. The company describes itself as a global leader in this rare blood disorder, and its news coverage reflects progress in clinical development, regulatory interactions, capital formation and corporate governance.
Many Immix Biopharma news items focus on its lead BCMA-targeted CAR-T cell therapy, NXC-201, and the ongoing NEXICART-2 clinical trial in relapsed/refractory AL amyloidosis. Press releases highlight interim and Phase 2 results, including complete response rates, organ responses and safety observations, as well as the selection of NXC-201 data for oral presentations at major conferences such as ASH and ASCO. The company also reports on regulatory designations for NXC-201, including RMAT and Orphan Drug Designation from U.S. and European authorities.
Investors following IMMX news will also see announcements about equity financings, including registered underwritten offerings and private placements of common stock and warrants, together with stated uses of proceeds for NXC-201 development and general corporate purposes. Additional coverage includes board and management changes, such as the appointment of experienced biotechnology leaders to the board of directors and the addition of a Chief Commercial Officer to prepare for potential commercialization of NXC-201.
This news page aggregates company press releases and related updates so readers can track Immix Biopharma’s clinical milestones, financing activities, conference presentations and strategic appointments over time.
Immix Biopharma reported promising results for its lead candidate IMX-110, demonstrating a 50% response rate in a study involving first-line-therapy-resistant soft tissue sarcoma (STS) mice, outperforming the standard treatment doxorubicin’s 0% response rate. This candidate is positioned in a lucrative market projected to grow from $2.9 billion in 2019 to $6.5 billion by 2030. Additionally, IMX-110 has received orphan drug and rare pediatric disease designations from the FDA, which could expedite its development and approval process.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced the IMMX Investors Day Event on February 1, 2022. An online Q&A platform is open for shareholders to submit questions until January 20. The live event will be webcasted on the Investor Relations website, and a replay will be provided afterward. ImmixBio specializes in Tissue Specific Therapeutics (TSTx) for oncology and immuno-dysregulated diseases, with a proprietary platform that enhances drug delivery. Investors are encouraged to participate and engage with management during this event.
Immix Biopharma (Nasdaq: IMMX) has received Rare Pediatric Disease Designation from the FDA for IMX-110, aimed at treating rhabdomyosarcoma, a life-threatening pediatric cancer. This designation may allow the company to obtain a Priority Review Voucher (PRV) upon marketing approval, potentially valued between $67 million to $350 million. IMX-110 is currently in a Phase 1b/2a clinical trial and has shown promising data, including a median progression-free survival of four months with no severe drug-related adverse events.
Immix Biopharma, Inc. (Nasdaq: IMMX) has successfully closed its initial public offering (IPO) of 4.2 million shares at $5.00 per share, raising $21 million. An additional 630,000 shares may be purchased by underwriters for over-allotments. The funds will support clinical trials for IMX-110 and other IND-enabling studies. The shares began trading on the Nasdaq Capital Market on December 16, 2021. ThinkEquity acted as the book-running manager for the offering. The company focuses on developing Tissue Specific Therapeutics for oncology and immuno-dysregulated diseases.
Immix Biopharma, Inc. (Nasdaq: IMMX) has priced its initial public offering (IPO) at $5.00 per share, aiming to raise $21 million before expenses. The offering consists of 4,200,000 shares, with an additional 630,000 shares available for overallotments. Trading on Nasdaq is set to begin on December 16, 2021, with the offering closing on December 20, 2021. Proceeds will fund a Phase 2a trial for IMX-110 in soft tissue sarcoma, a Phase 1b trial, and other corporate purposes. ThinkEquity is the sole book-running manager for this offering.